Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04085081
Other study ID # 19252
Secondary ID NCI-2019-0558219
Status Withdrawn
Phase N/A
First received
Last updated
Start date May 15, 2021
Est. completion date November 1, 2022

Study information

Verified date August 2021
Source City of Hope Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies whether a telephone-based physical activity intervention before and after lung cancer surgery can be provided to older patients and their caregivers. The trial also aims to understand whether patients and family caregivers will be satisfied with the intervention. Participating in physical activity such as walking before and after lung cancer surgery may improve functional status and recovery in older patients and their family caregivers.


Description:

PRIMARY OBJECTIVE: I. Administer and determine the feasibility of the perioperative physical activity intervention. SECONDARY OBJECTIVES: I. To describe patient and family caregiver outcome patterns and trajectory pre- and post-intervention. II. Using qualitative methods, evaluate the acceptability of the intervention through brief, semi-structured interviews with patients and family caregivers. OUTLINE: Patients and family caregivers complete comprehensive geriatric and functional assessments before surgery. This information is used to develop a personalized walking program plus simple lower extremity strength exercises. The intervention is administered by trained coaches with physical and occupational therapy background. The sessions are delivered by telephone before surgery (30-60 minutes), and on days 2, 7, 14, and 21 after hospital discharge (20-50 minutes). Participants will also receive brief motivational text or email messages (4 times per week between telephone sessions) to provide support, promote physical activity behavior change, and to sustain participant engagement. Patients and family caregivers are followed up to day 30 after hospital discharge.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 1, 2022
Est. primary completion date November 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - PATIENTS: Must have histologically confirmed non-small cell lung cancer (NSCLC) or carcinoid tumor of the lung, and registration must occur after the first histologic diagnosis - PATIENTS: Must be registered at least 15 days before their scheduled surgery - PATIENTS: Must be scheduled for a lobectomy (open or minimally invasive) - PATIENTS: Must have access to a smartphone or telephone for study intervention sessions and study text messages - PATIENTS: Age >= 70 years - PATIENTS: Must be willing to wear a wristband pedometer for the duration of the study period, except on day of surgery - PATIENTS: Must be willing to answer telephone calls from the City of Hope Call Center - PATIENTS: Must have an identified family member or friend who is enrolled in the study - PATIENTS: Able to read and comprehend English. Study materials and telephone calls are only available in English - FAMILY CAREGIVERS: Family member or friend identified by the patient and will be caring for the patient before and after surgery - FAMILY CAREGIVERS: Age >= 18 years - FAMILY CAREGIVERS: Must have access to a smartphone or telephone for study intervention sessions and study text messages - FAMILY CAREGIVERS: Must be willing to wear a wristband pedometer for the duration of the study period - FAMILY CAREGIVERS: Must be willing to answer telephone calls from the City of Hope Call Center - FAMILY CAREGIVERS: Must have a care recipient (patient) who is enrolled in the study - FAMILY CAREGIVERS: Able to read and comprehend English. Study materials and telephone calls are only available in English

Study Design


Intervention

Other:
E-mail
Receive brief motivational text or email messages
Behavioral:
Exercise Intervention
Receive personalized walking program plus strength exercises
Other:
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Behavioral:
Telephone-Based Intervention
Receive intervention coaching sessions via telephone
Other:
Text Message
Receive brief motivational text or email messages

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
City of Hope Medical Center National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Other Patient and family caregiver outcome patterns and trajectories before and after the intervention Descriptive statistics will be used to summarize all outcome measure scores using validated scoring procedures, and to explore patterns and trajectories over time. Baseline up to 30 days post-hospital discharge
Primary Enrollment of >= 70% of eligible participants Will be evaluated based on data obtained throughout the study. Descriptive statistics will be assessed using means, standard deviations, and ranges for continuous variables, and frequencies and percentages for categorical variables. Up to 30 days post-hospital discharge
Primary >= 70% of enrolled participants who answer the telephone calls from City of Hope interventionists Will be evaluated based on data obtained throughout the study. Descriptive statistics will be assessed using means, standard deviations, and ranges for continuous variables, and frequencies and percentages for categorical variables. Up to 30 days post-hospital discharge
Primary Adherence/engagement Will be determined by >= 70% of enrolled participants who complete at least 2 intervention sessions. Descriptive statistics will be assessed using means, standard deviations, and ranges for continuous variables, and frequencies and percentages for categorical variables. Up to 30 days post-hospital discharge
Secondary Intervention acceptability as reported by participants Acceptability will be assessed through qualitative data analysis of exit interviews using content analysis approach. Up to 30 days post-hospital discharge
See also
  Status Clinical Trial Phase
Withdrawn NCT04989283 - Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer Phase 2
Recruiting NCT05106374 - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Terminated NCT03707925 - Bronchoscopic Laser Ablation of Peripheral Lung Tumors N/A
Active, not recruiting NCT04013542 - Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer Phase 1
Not yet recruiting NCT06427369 - An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer Phase 1
Recruiting NCT04929041 - Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative Phase 2/Phase 3
Recruiting NCT04073745 - Single Fraction Stereotactic Body Radiation Therapy After Surgery in Treating Patients With Non-small Cell Lung Cancer Phase 1
Recruiting NCT05830058 - Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma Phase 2
Active, not recruiting NCT03637816 - Anamorelin Hydrochloride in Reducing Anorexia in Patients With Advanced Non-small Cell Lung Cancer Phase 2/Phase 3
Recruiting NCT04298606 - A Vaccine (CIMAvax-EGF) for the Prevention of Lung Cancer Development or Recurrence Early Phase 1
Recruiting NCT06122064 - A Tool for Improving the Shared Decision-making Process in Patients With Non-small Cell Lung Cancer N/A
Recruiting NCT05802186 - Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study N/A
Recruiting NCT03634241 - Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study Phase 2
Recruiting NCT04314401 - National Cancer Institute "Cancer Moonshot Biobank"
Recruiting NCT05493566 - Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer Early Phase 1
Suspended NCT05501665 - Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer Phase 1/Phase 2
Withdrawn NCT04061590 - Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Phase 2
Recruiting NCT06225427 - Gilteritinib for the Treatment of ALK NSCLC Phase 1
Active, not recruiting NCT03939481 - Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
Recruiting NCT05672108 - Transarterial Chemoembolization for the Treatment of Lung Cancer Phase 2